Immunogenicity of pembrolizumab in patients with advanced tumors
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Pembrolizumab is a potent, humanized, monoclonal anti-programmed death 1 antibody that has demonstrated effective antitumor activity and acceptable safety in multiple tumor types. Therapeutic biologics can result in the development of antidrug antibodies (ADAs), which may alter drug clearance and neutralize target binding, potentially reducing drug efficacy; such immunogenicity may also result in infusion reactions, anaphylaxis, and immune complex disorders. Pembrolizumab immunogenicity and its impact on exposure, safety, and efficacy was assessed in this study. PATIENTS AND METHODS: Pembrolizumab immunogenicity was assessed in 3655 patients with advanced or metastatic cancer treated in 12 clinical studies. Patients with melanoma, non-small cell lung cancer, head and neck squamous cell carcinoma, colorectal cancer, urothelial cancer, and Hodgkin lymphoma were treated with pembrolizumab at 2 mg/kg every 3 weeks, 10 mg/kg every 2 weeks, 10 mg/kg every 3 weeks, or 200 mg every 3 weeks. An additional study involving 496 patients with stage III melanoma treated with 200 mg adjuvant pembrolizumab every 3 weeks after complete resection was analyzed separately. RESULTS: Of 3655 patients, 2000 were evaluable for immunogenicity analysis, 36 (1.8%) were treatment-emergent (TE) ADA-positive; 9 (0.5%) of these TE-positive patients had antibodies with neutralizing capacity. The presence of pembrolizumab-specific ADAs did not impact pembrolizumab exposure, nor did pembrolizumab immunogenicity affect the incidence of drug-related adverse events (AEs) or infusion-related reactions. There was no clear relationship between the presence of pembrolizumab-specific ADAs and changes in tumor size across treatment regimens. Of the 496 patients treated with pembrolizumab as adjuvant therapy, 495 were evaluable, 17 (3.4%) were TE ADA-positive; none had neutralizing antibodies. CONCLUSIONS: The incidence of TE (neutralizing positive) ADAs against pembrolizumab was low in patients with advanced tumors. Furthermore, immunogenicity did not appear to have any clinically relevant effects on the exposure, safety, or efficacy of pembrolizumab. TRIAL REGISTRATION: ClinicalTrials.gov, NCT01295827 (February 15, 2011), NCT01704287 (October 11, 2012), NCT01866319 (May 31, 2013), NCT01905657 (July 23, 2013), NCT02142738 (May 20, 2014), NCT01848834 (May 8, 2013), NCT02255097 (October 2, 2014), NCT02460198 (June 2, 2015), NCT01953692 (October 1, 2013), NCT02453594 (May 25, 2015), NCT02256436 (October 3, 2014), NCT02335424 (January 9, 2015), NCT02362594 (February 13, 2015).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The detection of pembrolizumab ADAs (1.4%) and neutralizing antibodies (0.5%) among participants in the pembrolizumab s.c.arm was comparable to the results of an immunogenicity analysis of pembrolizumab i.v.(N ¼ 2000 assessable participants), in which ADAs were detected in 1.8% of participants and neutralizing antibodies in 0.5%.21”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Iwai, Y., Ishida, M., Tanaka, Y., Okazaki, T., Honjo, T., & Minato, N. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192461099 · Cited by 3,203
Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose
Chung, C. H., Mirakhur, B., Chan, E., Le, Q.-T., Berlin, J., Morse, M., Murphy, B. A., Satinover, S. M., Hosen, J., Mauro, D., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa074943 · Cited by 1,521
Patnaik, A., Kang, S. P., Rasco, D., Papadopoulos, K. P., Elassaiss-Schaap, J., Beeram, M., Drengler, R., Chen, C., Smith, L., Espino, G., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2607 · Cited by 807
PD‐1 as a potential target in cancer therapy
McDermott, D. F., & Atkins, M. B. (2013) · Cancer Medicine · doi:10.1002/cam4.106 · Cited by 414
Shankar, G., Arkin, S., Cocea, L., Devanarayan, V., Kirshner, S., Kromminga, A., Quarmby, V., Richards, S., Schneider, C. K., Subramanyam, M., et al. (2014) · The AAPS Journal · doi:10.1208/s12248-014-9599-2 · Cited by 353
Assessing Response and Loss of Response to Biological Therapies in IBD
Yanai, H., & Hanauer, S. B. (2011) · American Journal of Gastroenterology · doi:10.1038/ajg.2011.103 · Cited by 326
Lymphocyte depletion and repopulation after chemotherapy for primary breast cancer
Verma, R., Foster, R. E., Horgan, K., Mounsey, K., Nixon, H., Smalle, N., Hughes, T. A., & Carter, C. R. (2016) · Breast Cancer Research · doi:10.1186/s13058-015-0669-x · Cited by 269
Cited by
Signaling pathways involved in colorectal cancer: pathogenesis and targeted therapy
Li, Q., Geng, S., Luo, H., Wang, W., Mo, Y.-Q., Luo, Q., Wang, L., Song, G.-B., Sheng, J.-P., & Xu, B. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01953-7 · Cited by 546
Vaisman-Mentesh, A., Gutierrez-Gonzalez, M., DeKosky, B. J., & Wine, Y. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01951 · Cited by 292
Targeting PD-1/PD-L-1 immune checkpoint inhibition for cancer immunotherapy: success and challenges
Javed, S. A., Najmi, A., Ahsan, W., & Zoghebi, K. A. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1383456 · Cited by 121
Tumor-infiltrating CD8+ T cell antitumor efficacy and exhaustion: molecular insights
Kumar, S., Singh, S. K., Rana, B., & Rana, A. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.01.002 · Cited by 118
Siu, L. L., Wang, D., Hilton, J., Geva, R., Rasco, D., Perets, R., Abraham, A. K., Wilson, D. C., Markensohn, J. F., Lunceford, J., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2160 · Cited by 85
“Low ADA rates for MK-4830 were consistent with ADA rates previously observed in pembrolizumab monotherapy studies (19, 25).”
Result
Metadata
- Authors
- van Vugt, M. J. H., Stone, J. A., De Greef, “. H. J. M. M., Snyder, E. S., Lipka, L., Turner, D. C., Chain, A., Lala, M., Li, M., Robey, S. H., Kondic, A. G., De Alwis, D., Mayawala, K., Jain, L., & Freshwater, T.
- Affiliations
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Certara (United States) (US)
- Corresponding author
- Freshwater, Tomoko
- Venue
- Journal for ImmunoTherapy of Cancer
- Publisher
- BMJ
- Published
- 2019-08-08
- Volume
- 7
- Issue
- 1
- Pages
- 212-212
- ISSN
- 2051-1426 (ISSN-L)
- PMC
- PMC6686242
- OpenAlex
- W2967423315
- Cited by
- 57
- References
- 17
- Citations by year
- 2026: 5 · 2025: 10 · 2024: 13 · 2023: 6 · 2022: 7 · 2021: 11 · 2020: 4
- FWCI
- 2.30
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0/ (tdm)
- Locations
- Journal for ImmunoTherapy of Cancer (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA (NA)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Biosimilars and Bioanalytical Methods
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Keywords
- pembrolizumab, immunogenicity, antidrug antibodies, PD-1 inhibitors, neutralizing antibodies, drug exposure, infusion reactions, adjuvant therapy, melanoma, non-small cell lung cancer, head and neck squamous cell carcinoma, urothelial carcinoma, Hodgkin's disease, colorectal cancer, drug safety and efficacy
- MeSH terms
- Antineoplastic Agents, Immunological, Female, Humans, Male, Neoplasms, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Immunogenicity of pembrolizumab in patients with advanced tumors. https://app.cochat.ai/papers/10.1186/s40425-019-0663-4
- The paper
- van Vugt, M. J. H., Stone, J. A., De Greef, “. H. J. M. M., Snyder, E. S., Lipka, L., Turner, D. C., Chain, A., Lala, M., Li, M., Robey, S. H., Kondic, A. G., De Alwis, D., Mayawala, K., Jain, L., & Freshwater, T. (2019). Immunogenicity of pembrolizumab in patients with advanced tumors. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1186/s40425-019-0663-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.